Stock Financial Ratios

OPK / Opko Health, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price3.85
Volume2,463,500.00
Market Cap ($M)3,870.16
Enterprise Value ($M)3,660.98
Book Value ($M)2,091.81
Book Value / Share3.75
Price / Book1.06
NCAV ($M)-191.21
NCAV / Share4.54
Price / NCAV-10.64
Income Statement (mra) ($M)
Revenue1,221.66
EBITDA-73.28
Net Income-25.08
Balance Sheet (mrq) ($M)
Cash & Equivalents100.36
Cash / Share0.18
Assets0.00
Liabilities632.95
Quick Ratio1.66
Current Ratio1.84
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.01
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.01
Identifiers and Descriptors
CUSIP68375N103
Central Index Key (CIK)944809
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
68375N903
301610101
068375N10
68375N953
Share Statistics
Common Shares Outstanding558,221,985
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Cash Per Share0.18
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Debt Per Share0.03
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Non Current Per Share0.00
Equity Per Share3.74
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Accounts Receivable Per Share0.42
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Cash And Equivalents Per Share0.18
Liabilities Current Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Liabilities Per Share1.15
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Intangibles Per Share0.00
Assets Current Per Share0.77
Accumulated Depreciation And Depletion Per Share0.00
Inventory Per Share0.08

OPK : Opko Health Stock Analysis and Research Report

Opko Health is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Its diagnostics business includes BioReference Laboratories (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Opko Health's pharmaceutical business features Rayaldee , an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO in November 2015 and pending approval for IV formulation), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clini...

Click for full article

Related News Stories

Dish Network, Opko Health Sink into Wednesday’s 52-Week Low Club

2018-01-17 247wallst
January 17, 2018: Here are four stocks trading with heavy volume among 63 equities making new 52-week lows in Wednesday’s session. On the NYSE advancers led decliners by nearly 2 to 1 and on the Nasdaq, advancers led decliners by about the same ratio. (90-2)

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

2018-01-13 seekingalpha
Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib. (254-7)

Why OPKO Health (OPK) Could Be Positioned for a Slump

2017-11-27 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. (98-4)

OPKO Health: A House Of Cards Tumbling In The Dark

2017-11-17 seekingalpha
A slew of undisclosed or thinly disclosed executive team departures in the diagnostics division, which represents over 82.8% of revenue, could signal business decline and a compliance “house-cleaning”. (73-3)

Cramer's lightning round: Opko Health is a 'neighborhood of pain'

2017-11-16 cnbc
Opko Health Inc.: "Oh my god, the quarter, not good. I mean, this thing has become a genuine house of pain. No, this is like a neighborhood of pain. And until [CEO] Dr. Frost comes on, we're going to back away. We have to. We have to." (207-2)

CUSIP: 68375N103